Treatment Patterns and Survival Outcomes Among Patients With Hepatocellular Carcinoma
In this cohort study of patients treated with systemic therapy for HCC between 2011 and 2023, atezolizumab-bevacizumab and durvalumab-tremelimumab emerged as the most common first-line systemic therapies administered for HCC, but relatively few patients received second-line therapy. Additional research is needed to determine optimal treatment sequencing and increase the likelihood that patients may benefit from second-line systemic therapy options.
Authors
- Franklin Iheanacho (ORCID: https://orcid.org/0000-0003-2909-1500)
- Angela C. Tramontano (ORCID: https://orcid.org/0000-0001-5718-6297)
- Thomas A. Abrams (ORCID: https://orcid.org/0000-0003-3101-1573)
- Kelsey S. Lau-Min
- Christopher R. Manz
Institutions
- Harvard University (US)
- Brown University (US)
- Massachusetts General Hospital (US)
- Dana-Farber Cancer Institute (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-12-30
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.51665
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- GlaxoSmithKline
- National Institutes of Health